Short answer
Labcorp (LH) filed an 8-K current report with the SEC on September 22, 2026 reporting Item 7.01 (Regulation FD Disclosure). CMS preliminary 2027–2029 rates imply steep annual PAMA reimbursement cuts, creating material pressure on Labcorp’s Medicare revenue and patient access.
Labcorp 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- CMS preliminary 2027–2029 rates imply steep annual PAMA reimbursement cuts, creating material pressure on Labcorp’s Medicare revenue and patient access
- Labcorp reaffirmed 2026–2029 outlook despite CMS proposal: 5%–8% revenue CAGR
- Long-term targets include 75–150 basis points adjusted operating-margin expansion by 2029
- Adjusted EPS and free cash flow targeted to grow 8.5%–11.5% annually
- 2027 guidance impact remains under evaluation, with details expected in February 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Labcorp 8-K filings
Get the next LH 8-K as it lands
Follow LH for push alerts, or ask the research agent what this filing means.